Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pembrolizumab + carboplatin/taxane ± MK-2870 in first-line metastatic squamous NSCLC
jRCT2021240015Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of pembrolizumab and sacituzumab tirumotecan in Pulmonary squamous cell carcinoma (3 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Started Jan 2025; status: recruiting.
02
Drugs
pembrolizumabsacituzumab tirumotecan
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2021240015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240015.